Lilly Diabetes Sales Growth Slows; Newer Products Take The Lead
Executive Summary
Despite efforts to strengthen its position in the diabetes market, revenue from Lilly's diabetes care franchise - Humulin, Humalog, Actos and Byetta - increased just 5% to $701.7 mil. in the second quarter, primarily on the strength of Byetta